MET and non-small cell lung carcinoma: For example, in non-small cell lung cancer (NSCLC), resistance to EGFR-selective TKIs occurs via gatekeeper mutations in EGFR, selection for MET amplification, and perhaps other mechanisms including the induction of FGFR-dependent bypass pathways [15–18].